XLON
PXS
Market cap38mUSD
Jul 09, Last price
1.22GBP
1D
-2.40%
1Q
28.42%
Jan 2017
43.53%
IPO
-80.41%
Name
Provexis PLC
Chart & Performance
P/E
—
P/S
22.15
EPS
—
Div Yield, %
—
Shrs. gr., 5y
2.79%
Rev. gr., 5y
20.01%
Revenues
1m
+61.13%
Net income
-453k
L-22.78%
CFO
-341k
L+77.98%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Operating globally, Provexis plc, along with its associated companies, specializes in the creation, licensing, and commercialization of functional foods, medical nutritional products, and dietary supplements. A key offering is Fruitflow, a unique tomato extract designed to reduce the tendency for abnormal blood clot formation, which is linked to severe cardiovascular conditions such as heart attacks and strokes. This versatile extract is available in syrup and powder formats for integration into various food and beverage items, as well as dietary supplements. The company also provides Fruitflow + Omega-3, a capsule-based supplement aimed at fostering healthy blood circulation and supporting normal cardiac function. Provexis plc holds a strategic collaboration agreement with By-Health Co., Ltd. Its products are distributed through both physical retail channels and digital online platforms. Founded in 1999, Provexis plc has its headquarters situated in Reading, United Kingdom.
Valuation
Title GBP in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑03 | 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||